ライフサイエンスコーパス: irbesartan

1 mean sitting DBP and SBP, respectively, for irbesartan).

2 n coronary artery disease patients receiving irbesartan.

3 he presence of the AT(1) receptor antagonist irbesartan.

4 effect of that dose when coadministered with irbesartan.

5 Safety of sparsentan was similar to irbesartan.

6 TEAEs with sparsentan were similar to irbesartan.

7 F-PEF) on patients' lives and the effects of irbesartan.

8 specific mortality rates between placebo and irbesartan.

9 ibrosis that was prevented by treatment with irbesartan.

10 nvolved, Ang II was added in the presence of irbesartan (10 micromol/L), a specific AT(1) receptor an

11 re made over 24 h following randomization to irbesartan 12.5 mg, 37.5 mg, 75 mg, 150 mg or placebo.

12 f aliskiren 150 mg was comparable to that of irbesartan 150 mg (8.9+/-0.7 and 12.5+/-1.2 mm Hg, least

13 red mean sitting DBP significantly more than irbesartan 150 mg (P<0.05).

14 Aliskiren 150 mg is as effective as irbesartan 150 mg in lowering blood pressure.

15 or an indistinguishable monotherapy control (irbesartan 150 mg).

16 al doses of aliskiren (150, 300, or 600 mg), irbesartan 150 mg, or placebo.

17 bolic syndrome in a double-blinded manner to irbesartan 150 mg/d (n=14), lipoic acid 300 mg/d (n=15),

18 Patients were randomized 1:1 to receive irbesartan (150 mg/day titrated to 300 mg/day) or placeb

19 quickly accessing the antihypertensive drug irbesartan (2).

20 ber of AT(1) receptor antagonists, including irbesartan (3).

21 o to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated gl

22 th indapamide 1.5 mg/d, ramipril 10 mg/d (or irbesartan 300 mg/d), and amlodipine 10 mg/d were random

23 thy due to type 2 diabetes to treatment with irbesartan (300 mg daily), amlodipine (10 mg daily), or

24 ressure-lowering drugs each at quarter-dose (irbesartan 37.5 mg, amlodipine 1.25 mg, hydrochlorothiaz

25 aily caloric intake); 6 received alcohol and irbesartan (5 mg.kg(-1).d(-1) PO); and 8 were controls.

26 ge -5.9+/-0.9 mm Hg and -5.3+/-0.9 mm Hg for irbesartan 75 mg and 150 mg, respectively) after 12 week

27 Irbesartan, a long acting selective angiotensin-1 recept

28 vement in MLHFQ scores was not observed with irbesartan after 6 months (mean adjusted difference, 0.4

29 Treatment with irbesartan, aliskiren and amlodipine were associated wit

30 lly induced RAS, RAS + treatment with either irbesartan, aliskiren or amlodipine or sham-surgery.

31 (I-Preserve) trial and to determine whether irbesartan altered the distribution of mode of death in

32 e interaction of assigned study medications (irbesartan, amlodipine, and placebo) on progressive rena

33 diabetes and overt nephropathy treated with irbesartan, amlodipine, or placebo in addition to conven

34 Patients were randomized to irbesartan, amlodipine, or placebo, with other antihyper

35 Treatment with irbesartan, amlodipine, or placebo.

36 ound 7 clearly demonstrated superiority over irbesartan (an AT(1) receptor antagonist) in the normal

37 st, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 we

38 We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic

39 The AT(1)R blockers irbesartan and candesartan abrogated antifibrotic signal

40 /d (n=14), lipoic acid 300 mg/d (n=15), both irbesartan and lipoic acid (n=15), or matching placebo (

41 contrast, the highest cancer signals for the irbesartan and losartan recalls detected in March 2019 (

42 Conversely, irbesartan and losartan were largely G protein-selective

43 rol exposures, while the changes in RORs for irbesartan and losartan were only 20-30% higher.

44 rtan-associated cancer signals compared with irbesartan and losartan, although they all contained the

45 Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1

46 d tolerability profile comparable to that of irbesartan and placebo, in patients with mild-to-moderat

47 le were the formation of valsartan acid from irbesartan and valsartan, the persistence of N-desmethyl

48 Administration of irbesartan and/or lipoic acid to patients with the metab

49 Treatment with irbesartan and/or lipoic acid was associated with statis

50 40.3+/-11.3 years of age) were randomized to irbesartan, and 28 (64% female; 40.7+/-11.0 years of age

51 gliflozin, finerenone, atrasentan, losartan, irbesartan, and aliskiren in patients with CKD.

52 nals of association between ARBs (valsartan, irbesartan, and losartan) and reported neoplasm AEs usin

53 he exaggerated renal vasodilator response to irbesartan, and the therapeutic effectiveness of interru

54 , that started with the quadpill (containing irbesartan at 37.5 mg, amlodipine at 1.25 mg, indapamide

55 Irbesartan, at once-daily doses of 75 mg and 150 mg, ind

56 ed for telemesartan and, to a lesser extent, irbesartan based on a partial agonist action on PPAR-gam

57 All of these effects were inhibited by irbesartan but not PD 123319 or divalinil.

58 weeks with the angiotensin receptor blocker irbesartan, but not with the thiazide-type diuretic chlo

59 dividuals were enrolled in the international Irbesartan Diabetic Nephropathy Trial (IDNT) and followe

60 iabetic nephropathy and were enrolled in the Irbesartan Diabetic Nephropathy Trial (IDNT) and had a b

61 tensive patients with type 2 diabetes in the Irbesartan Diabetic Nephropathy Trial (IDNT), a randomiz

62 L) trial with independent replication in the Irbesartan Diabetic Nephropathy Trial (IDNT).

63 The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of s

64 Treatment with irbesartan did not affect overall mortality or the distr

65 Irbesartan did not improve the outcomes of patients with

66 Irbesartan did not substantially improve MLHFQ scores du

67 change in aortic Z score was also reduced by irbesartan (difference in means -0.10 per year, 95% CI -

68 placebo were reallocated to one of the four irbesartan doses, treatment was continued for 12 weeks a

69 ed coronary artery disease were treated with irbesartan for a 12-week period.

70 onary artery disease (CAD) were treated with irbesartan for a 24-week period.

71 e Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events, there was

72 sparsentan versus -4.4%, -15.8 to 8.7, with irbesartan; geometric least-squares mean ratio 0.60, 95%

73 er in the sparsentan group (-49.8%) than the irbesartan group (-15.1%), resulting in a between-group

74 0% lower in the sparsentan group than in the irbesartan group (-42.8%, 95% CI -49.8 to -35.0, with sp

75 h the risk related to WRF was greater in the irbesartan group (HR: 1.66; 95% CI: 1.21 to 2.28; p = 0.

76 group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0.7, 95% CI 0.4 to 1.2).

77 line aortic root diameter was 34.4 mm in the irbesartan group (SD 5.8) and placebo group (5.5).

78 mary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group.

79 .53 mm per year (95% CI 0.39 to 0.67) in the irbesartan group compared with 0.74 mm per year (0.60 to

80 group (P=0.003) and 37 percent lower in the irbesartan group than in the amlodipine group (P<0.001).

81 ne concentration was 33 percent lower in the irbesartan group than in the placebo group (P=0.003) and

82 tion increased 24 percent more slowly in the irbesartan group than in the placebo group (P=0.008) and

83 igned to the sparsentan group and 203 to the irbesartan group.

84 lower rate of eGFR decline than those in the irbesartan group.

85 ere not different between the sparsentan and irbesartan groups.

86 es in mortality rate between the placebo and irbesartan groups.

87 In contrast, patients receiving irbesartan had a significantly lower incidence of conges

88 from acute lung injury by the AT1 antagonist irbesartan; however, this effect was again blocked by A7

89 The ARB was losartan in 17 patients and irbesartan in 1 patient.

90 The study examines sparsentan versus irbesartan in adults (aged >=18 years) with biopsy-prove

91 ngful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy.

92 afety of the angiotensin II receptor blocker irbesartan in adults with vascular Ehlers-Danlos syndrom

93 We used data from the AVOID study and the Irbesartan in Diabetic Nephropathy Trial (IDNT) to estim

94 erved Ejection Fraction (PARAGON-HF) and the Irbesartan in Heart Failure With Preserved Ejection Frac

95 The I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Frac

96 istics and outcomes in the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Frac

97 n 3,595 patients included in the I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Frac

98 s and outcomes of patients with HFpEF in the Irbesartan in Heart Failure with Preserved Ejection Frac

99 lure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Frac

100 death in patients with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Frac

101 tality and morbidity) (EF>=45%), I-Preserve (Irbesartan in heart failure with Preserved ejection frac

102 ved Systolic Function [TOPCAT]; NCT00094302; Irbesartan in Heart Failure With Preserved Systolic Func

103 raction patients enrolled in the I-Preserve (Irbesartan in Heart Failure With Preserved Systolic Func

104 nd Preserved Systolic Function], I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Func

105 es by international geographic region in the Irbesartan in Heart Failure with Preserved systolic func

106 in these trials, along with the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Func

107 The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 pat

108 preserved ejection fraction enrolled in the irbesartan in patients with heart failure and preserved

109 ong-term hemodynamic and clinical effects of irbesartan in patients with heart failure.

110 nt with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in

111 Therefore, we studied the effects of irbesartan in patients with this syndrome.

112 Treatment with irbesartan in these patients significantly reduced level

113 RA, renal perfusion rose more in response to irbesartan in type 2 diabetes mellitus (714 +/- 83 to 93

114 e daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matchin

115 An additional renoprotective effect of irbesartan, independent of achieved SBP, was observed do

116 Irbesartan induced significant dose-related decreases in

117 Irbesartan is an orally active antagonist of the angiote

118 Irbesartan is associated with a reduction in the rate of

119 The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progre

120 ry was increased by 67%, 44%, and 75% in the irbesartan, lipoic acid, and irbesartan plus lipoic acid

121 sent in recalled products include valsartan, irbesartan, losartan, metformin, ranitidine, and nizatid

122 Our results show that use of irbesartan may retard the inflammatory process seen in p

123 Our results indicate that irbesartan may suppress the atherosclerotic process by i

124 PRA rose in response to irbesartan more gradually in the patients with type 2 di

125 seven dogs treated with the receptor blocker irbesartan (MR+AT(1)RB) started 24 h after induction of

126 ants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were follo

127 e randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment.

128 The effect of irbesartan on each inflammatory marker is significant.

129 We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children

130 aily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomi

131 participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg

132 In addition, treatment with irbesartan or irbesartan plus lipoic acid decreased 8-is

133 randomly assigned them to receive 300 mg of irbesartan or placebo per day.

134 ) and development of WRF after initiation of irbesartan or placebo were examined.

135 Patients were randomized to receive irbesartan or placebo.

136 r either the angiotensin-II-receptor blocker irbesartan or the calcium-channel blocker amlodipine slo

137 sm AEs were 2-fold higher for valsartan than irbesartan (OR, 1.77 [95% CI, 1.47-2.13], P<0.0001) and

138 With alcohol plus irbesartan, plasma Ang II, cardiac angiotensin-convertin

139 In addition, treatment with irbesartan or irbesartan plus lipoic acid decreased 8-isoprostane leve

140 and 75% in the irbesartan, lipoic acid, and irbesartan plus lipoic acid groups, respectively, compar

141 Irbesartan prevented the alcohol-induced decreases in LV

142 Compared with placebo, irbesartan reduced the risk of severe symptomatic and as

143 Eleven episodes of irbesartan-related hypotension were recorded, leading to

144 Treatment with the AT1 receptor blocker, irbesartan rescued the systolic dysfunction, normalized

145 gmented effect through coadministration with irbesartan, respectively.

146 Treatment with irbesartan significantly decreased the pro-oxidative env

147 Irbesartan significantly reduced systolic blood pressure

148 e global, randomized clinical trials testing irbesartan, spironolactone, sacubitril/valsartan, and da

149 t dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once dail

150 onsymptomatic arterial events was lower with irbesartan than with placebo (risk ratio, 0.37 [95% CI,

151 sly reported in HFrEF but more frequent with irbesartan than with placebo.

152 erability comparable to those of placebo and irbesartan; the incidence of adverse events and number o

153 ximal suppression of inflammatory markers by irbesartan therapy in patients with CAD was seen at 12 w

154 ) patients and occurred more frequently with irbesartan treatment (8% vs. 4%).

155 Estimated GFR decreased early with irbesartan treatment and remained significantly lower th

156 WRF after initiation of irbesartan treatment in HFpEF was associated with excess

157 symptomatic HF-PEF were randomly assigned to irbesartan (up to 300 mg daily) or placebo.

158 Also, venlafaxine, acesulfame, bezafibrate, irbesartan, valsartan, ibuprofen and naproxen displayed

159 from the sartan family: losartan potassium, irbesartan, valsartan, olmesartan medoxomil, and telmisa

160 curred in 8 of 29 patients (27.6%) receiving irbesartan versus 15 of 28 patients (53.6%) receiving pl

161 Treatment with irbesartan was associated with a relative risk of end-st

162 Treatment with irbesartan was associated with a risk of the primary com

163 In addition, the AT1 receptor blocker irbesartan was evaluated for its ability to suppress the

164 Irbesartan was well tolerated with no observed differenc

165 Irbesartan was well tolerated without evidence of dose-r

166 The neurohormonal effects of irbesartan were highly variable and none of the changes

167 ses of an angiotensin II (AngII) antagonist, irbesartan, were assessed in eight healthy volunteers an

168 est rise in renal plasma flow in response to irbesartan, whereas renal plasma flow rose less and GFR

169 present in an AT(1) receptor antagonist (1, irbesartan) with key structural elements in a biphenylsu

170 ts were well balanced between sparsentan and irbesartan, with no new safety signals.

171 ose of the biphenyl AT(1) antagonists (e.g., irbesartan) would yield a compound with dual activity fo